IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)

NCT04663399 | Recruiting

• 1 other identifier: BMR_2020_32
• Study Type: observational
• Target: 1,200
• Locations: 1 country
• Sites: 1

Brief Summary

IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.

Conditions

Ischemic Stroke; Thrombectomy

Outcome Measures

Primary Outcomes (1)

• Immuno-inflammatory and thrombo-inflammatory profiles in patients suffering from AIC and treated with mechanical Thrombectomie.

  Blood plasma collected from patients at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment will be used to discover and validate panels of inflammatory biomarkers that are predictive of therapeutic response. The biomarkers will be measured using a multiplex preconfigured panels for inflammatory biomarkers.

  21 months

Study Arms (2)

Patient with MT

Patients indicated for mechanical thrombectomy and benefiting from the procedure

Other: Prospective patient

Patient without MT

Patients indicated for mechanical thrombectomy but not benefiting from the intervention due to clinical improvement (patients responding to thrombolysis)

Other: Prospective patient

Interventions

Prospective patient OTHER

The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.

Patient with MT; Patient without MT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients referred for a mechanical thrombectomy as part of an acute ischemic stroke will be able to participate in the study.

You may qualify if:

• Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,
• Affiliated or beneficiary of a social security scheme or equivalent.
• Pregnant or breast-feeding women
• Patient benefiting from a legal protection measure

You may not qualify if:

• None.

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (1)

Hôpital Fondation Adolphe de Rothschild

Paris, Paris, 75019, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Each blood sample consists of 3x3 mL Citrate + 1x4 mL EDTA + 1x4 mL Heparin + 1x5 mL dry tube.

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Benjamin Maier, MD

  Fondation Ophtalmologique Adolphe de Rothschild

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Benjamin Maier, MD

CONTACT

0148036556; bmaier@for.paris

Amélie Yavchitz, MD

CONTACT

0148036556; ayavchitz@for.paris

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 25, 2020
• First Posted: December 11, 2020
• Study Start: February 23, 2023
• Primary Completion (Estimated): May 23, 2028
• Study Completion (Estimated): May 23, 2028
• Last Updated: January 23, 2026

Record last verified: 2026-01

Locations

FR (1)